John T Lear

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3817722/publications.pdf

Version: 2024-02-01

		218592	161767
59	3,043	26	54
papers	citations	h-index	g-index
60	60	60	3345
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Non-melanoma skin cancer. Lancet, The, 2010, 375, 673-685.	6.3	716
2	Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncology, The, 2015, 16, 716-728.	5.1	325
3	Association between functional polymorphism in EGF gene and malignant melanoma. Lancet, The, 2002, 359, 397-401.	6.3	244
4	The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. Journal of the American Academy of Dermatology, 2016, 75, 113-125.e5.	0.6	133
5	Multiple cutaneous basal cell carcinomas: glutathione S-transferase (GSTM1, GSTT1) and cytochrome P450 (CYP2D6, CYP1A1) polymorphisms influence tumour numbers and accrual. Carcinogenesis, 1996, 17, 1891-1896.	1.3	110
6	Photodynamic Therapy With Methyl Aminolevulinate for Prevention of New Skin Lesions in Transplant Recipients: A Randomized Study. Transplantation, 2008, 86, 423-429.	0.5	94
7	Clinical and Immunologic Results of a Phase II Trial of Sequential Imiquimod and Photodynamic Therapy for Vulval Intraepithelial Neoplasia. Clinical Cancer Research, 2008, 14, 5292-5299.	3.2	89
8	Associations between ultraviolet radiation, basal cell carcinoma site and histology, host characteristics, and rate of development of further tumors. Journal of the American Academy of Dermatology, 2005, 52, 468-473.	0.6	73
9	Cutaneous basal cell carcinomas. Cancer, 2001, 92, 354-358.	2.0	66
10	Non-melanoma skin cancer. Clinical Medicine, 2016, 16, 62-65.	0.8	66
11	Glutathione S-transferase polymorphisms: influence on susceptibility to cancer. Chemico-Biological Interactions, 1998, 111-112, 351-364.	1.7	63
12	Photodynamic Therapy and Non-Melanoma Skin Cancer. Cancers, 2016, 8, 98.	1.7	63
13	Emerging trends in the treatment of advanced basal cell carcinoma. Cancer Treatment Reviews, 2018, 64, 1-10.	3.4	63
14	Susceptibility to Melanoma: Influence of Skin Type and Polymorphism in the Melanocyte Stimulating Hormone Receptor Gene. Journal of Investigative Dermatology, 1998, 111, 218-221.	0.3	60
15	Truncal Tumor Site Is Associated with high Risk of Multiple Basal Cell Carcinoma and Is Influenced by Glutathione S-Transferase, GSTT1, and Cytochrome P450, CYP1A1 Genotypes, and Their Interaction. Journal of Investigative Dermatology, 1997, 108, 519-522.	0.3	56
16	Retrospective review of the use of azathioprine in severe atopic dermatitis. Journal of the American Academy of Dermatology, 1996, 35, 642-643.	0.6	44
17	Azathioprine. BioDrugs, 1998, 9, 33-47.	2.2	42
18	Polymorphism in the nuclear excision repair geneERCC2/XPD: association between an exon 6-exon 10 haplotype and susceptibility to cutaneous basal cell carcinoma. Human Mutation, 2005, 25, 353-359.	1.1	42

#	Article	IF	CITATIONS
19	Management of high-risk squamous cell carcinoma of the skin. Expert Review of Anticancer Therapy, 2011, 11, 763-769.	1.1	42
20	Combined effects of gender, skin type and polymorphic genes on clinical phenotype: use of rate of increase in numbers of basal cell carcinomas as a model system. Cancer Letters, 2003, 189, 175-181.	3.2	41
21	Oral Hedgehog-Pathway Inhibitors for Basal-Cell Carcinoma. New England Journal of Medicine, 2012, 366, 2225-2226.	13.9	41
22	Basal cell carcinoma. Cancer, 2000, 89, 1012-1018.	2.0	40
23	Basal cell carcinomas: association of allelic variants with a high-risk subgroup of patients with the multiple presentation phenotype. Pharmacogenetics and Genomics, 2001, 11, 247-254.	5.7	39
24	Cytochrome P450 CYP2D6 genotypes. Pharmacogenetics and Genomics, 1999, 9, 269-276.	5.7	37
25	Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases. Plastic and Reconstructive Surgery - Global Open, 2017, 5, e1424.	0.3	36
26	Glutathione S-transferase GSTP1 and cyclin D1 genotypes: association with numbers of basal cell carcinomas in a patient subgroup at high-risk of multiple tumours. Pharmacogenetics and Genomics, 2000, 10, 545-556.	5.7	35
27	Focus on Basal Cell Carcinoma. Journal of Skin Cancer, 2011, 2011, 1-5.	0.5	27
28	The melanocyte stimulating hormone receptor polymorphism: association of the V92M and A294H alleles with basal cell carcinoma. Clinica Chimica Acta, 1999, 282, 125-134.	0.5	23
29	Use of Photodynamic Therapy for Treatment of Actinic Keratoses in Organ Transplant Recipients. BioMed Research International, 2013, 2013, 1-7.	0.9	22
30	Evidence for field cancerisation treatment of actinic keratoses with topical diclofenac in hyaluronic acid. European Journal of Dermatology, 2014, 24, 158-167.	0.3	21
31	Associations between UVR exposure and basal cell carcinoma site and histology. Cancer Letters, 2004, 216, 191-197.	3.2	19
32	Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma. Journal of the American Academy of Dermatology, 2009, 61, 247-251.	0.6	19
33	Nodular basal cell carcinoma in Gorlin's syndrome treated with systemic photodynamic therapy and interstitial optical fiber diffuser laser. Journal of the American Academy of Dermatology, 2006, 55, S86-S89.	0.6	18
34	The Role of Ingenol Mebutate in the Treatment of Actinic Keratoses. Dermatology and Therapy, 2012, 2, 8.	1.4	17
35	Contact sensitivity in patients with oral symptoms. Contact Dermatitis, 1998, 39, 258-259.	0.8	15
36	Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments). British Journal of Dermatology, 2022, 187, 324-337.	1.4	15

#	Article	IF	Citations
37	PTCH polymorphism is associated with the rate of increase in basal cell carcinoma numbers during follow-up: Preliminary data on the influence of an exon 12-exon 23 haplotype. Environmental and Molecular Mutagenesis, 2004, 44, 469-476.	0.9	14
38	<p>Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial</p> . Clinical, Cosmetic and Investigational Dermatology, 2020, Volume 13, 117-121.	0.8	14
39	Contact sensitivity and systemic reaction to pseudoephedrine and lignocaine. Contact Dermatitis, 1998, 39, 33-33.	0.8	13
40	Patients With Truncal Basal Cell Carcinoma Represent a High-Risk Group. Archives of Dermatology, 1998, 134, 373.	1.7	13
41	Susceptibility and modifier genes in cutaneous basal cell carcinomas and their associations with clinical phenotype. Journal of Photochemistry and Photobiology B: Biology, 2001, 63, 1-7.	1.7	13
42	Tests to assist in the diagnosis of keratinocyte skin cancers in adults: a generic protocol. The Cochrane Library, 0 , , .	1.5	13
43	The rate of increase in the numbers of primary sporadic basal cell carcinomas during follow up is associated with age at first presentation. Carcinogenesis, 2002, 23, 2051-2054.	1.3	11
44	Defining locally advanced basal cell carcinoma and integrating smoothened inhibitors into clinical practice. Current Opinion in Oncology, 2016, 28, 180-184.	1.1	11
45	Melanoma in Organ Transplant Recipients: Incidence, Outcomes and Management Considerations. Journal of Skin Cancer, 2012, 2012, 1-5.	0.5	10
46	Common variants modify the age of onset for basal cell carcinomas in Gorlin syndrome. European Journal of Human Genetics, 2015, 23, 708-710.	1.4	10
47	Photodynamic therapy corrects abnormal cancer-associated gene expression observed in actinic keratosis lesions and induces a remodeling effect in photodamaged skin. Journal of Dermatological Science, 2018, 91, 206-218.	1.0	10
48	The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma. Expert Review of Anticancer Therapy, 2016, 16, 1011-1018.	1.1	9
49	Ingenol mebutate: a novel treatment for actinic keratosis. Clinical Practice (London, England), 2014, 11, 295-306.	0.1	8
50	Increasing Capacity for Skin Surveillance in a Transplant Review Clinic. Transplantation, 2014, 97, e48-e50.	0.5	7
51	Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42Âmonths. Journal of the American Academy of Dermatology, 2021, 84, 1162-1164.	0.6	7
52	Evidence-based treatment for low-risk basal cell carcinoma. Lancet Oncology, The, 2014, 15, 12-13.	5.1	6
53	Sequential Treatment of Multiple Actinic Keratoses with Solaraze and Actikerall. Case Reports in Dermatology, 2014, 6, 164-168.	0.3	5
54	Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma. Oncotarget, 2021, 12, 2531-2540.	0.8	5

#	Article	IF	CITATIONS
55	Skin Cancer: Basal cell carcinoma: genetic homogeneity in a tumour type displaying phenotypic diversity. European Journal of Human Genetics, 2006, 14, 977-978.	1.4	2
56	Nonsurgical treatment options for nonmelanoma skin cancers. Expert Review of Dermatology, 2007, 2, 59-67.	0.3	2
57	Expression of Glioma-associated oncogene homolog 1 as biomarker with sonidegib in advanced basal cell carcinoma. Oncotarget, 2020, 11 , 3473 - 3483 .	0.8	2
58	Pathergy. Cmaj, 2007, 176, 1275-1276.	0.9	0
59	Mitigating the risk of skin cancer associated with thiopurine use. British Journal of Hospital Medicine (London, England: 2005), 2014, 75, 55-55.	0.2	0